General Information |
| Summary |
This is a single centre, single arm, open-label study, to investigate the safety and efficacy of Autologous induced islet body With Type 1 diabetes. |
| Clinical trials phase |
Other |
| Start date (estimated) |
2019-01-01 |
| End date (estimated) |
2021-01-31 |
| Clinical feature |
| Label |
type 1 diabetes mellitus |
| Link |
http://purl.obolibrary.org/obo/DOID_9744 |
| Description |
A diabetes mellitus that is characterized by destruction of pancreatic beta cells resulting in absent or extremely low insulin production.; Xref MGI. OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| NCT number |
NCT03728296 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT03728296 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/ct2/show/NCT03728296 |
| Sponsors |
Allife Medical Science and Technology Co., Ltd.
|
Cells |
| Which differentiated cell type is used |
| Label |
islet of Langerhans |
| Link |
http://purl.obolibrary.org/obo/UBERON_0000006 |
| Description |
The clusters of hormone-producing cells that are scattered throughout the pancreas. |
|
Recruitment |
| Recruitment Status |
Not yet recruiting |
| Estimated number of participants |
20 |
